March 2018 Arizona Thoracic Society notes

No abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing...

Full description

Bibliographic Details
Main Author: Robbins RA
Format: Article
Language:English
Published: Arizona Thoracic Society 2018-03-01
Series:Southwest Journal of Pulmonary and Critical Care
Subjects:
Online Access:http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.html
id doaj-ca23de10dd834ed28612014837fed3b0
record_format Article
spelling doaj-ca23de10dd834ed28612014837fed3b02020-11-24T22:04:17ZengArizona Thoracic SocietySouthwest Journal of Pulmonary and Critical Care2160-67732018-03-0116317017110.13175/swjpcc051-18March 2018 Arizona Thoracic Society notesRobbins RA0Phoenix Pulmonary and Critical Care Research and Education Foundation, Gilbert, AZ USANo abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing the pulmonary, critical care, sleep, infectious disease and radiology communities. At the beginning of the meeting several issues were discussed: 1. The Tobacco 21 which had been introduced into the Arizona House was killed in committee by Rep. Jeff Weninger, Chairman of the Commerce Committee. 2. Council of Chapter Representatives (CCR) Meeting and “Hill Day” was cancelled due to inclement weather. It will probably be rescheduled for the summer. An update on pirfenidone in IPF was presented by Jessica Castle, PhD, Medical Science Liaison with Genentech. Dr. Castle discussed the antifibrotic, anti-inflammatory, and anti-oxidant effects of pirfenidone. Data was also presented from post-hoc analysis from pirfenidone trials. • Overall no difference in morality data …http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.htmlYersinia pestisgangrenetobacco 21continuous sympathetic blockadetriad asthmacoronary artery spasmhypersensitivity pneumonitispirfenidoneidiopathic pulmonary fibrosismortality
collection DOAJ
language English
format Article
sources DOAJ
author Robbins RA
spellingShingle Robbins RA
March 2018 Arizona Thoracic Society notes
Southwest Journal of Pulmonary and Critical Care
Yersinia pestis
gangrene
tobacco 21
continuous sympathetic blockade
triad asthma
coronary artery spasm
hypersensitivity pneumonitis
pirfenidone
idiopathic pulmonary fibrosis
mortality
author_facet Robbins RA
author_sort Robbins RA
title March 2018 Arizona Thoracic Society notes
title_short March 2018 Arizona Thoracic Society notes
title_full March 2018 Arizona Thoracic Society notes
title_fullStr March 2018 Arizona Thoracic Society notes
title_full_unstemmed March 2018 Arizona Thoracic Society notes
title_sort march 2018 arizona thoracic society notes
publisher Arizona Thoracic Society
series Southwest Journal of Pulmonary and Critical Care
issn 2160-6773
publishDate 2018-03-01
description No abstract available. Article truncated after 150 words. The March 2018 Arizona Thoracic Society meeting was held on Wednesday, March 28, 2018 at the HonorHealth Rehabilitation Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were 12 in attendance representing the pulmonary, critical care, sleep, infectious disease and radiology communities. At the beginning of the meeting several issues were discussed: 1. The Tobacco 21 which had been introduced into the Arizona House was killed in committee by Rep. Jeff Weninger, Chairman of the Commerce Committee. 2. Council of Chapter Representatives (CCR) Meeting and “Hill Day” was cancelled due to inclement weather. It will probably be rescheduled for the summer. An update on pirfenidone in IPF was presented by Jessica Castle, PhD, Medical Science Liaison with Genentech. Dr. Castle discussed the antifibrotic, anti-inflammatory, and anti-oxidant effects of pirfenidone. Data was also presented from post-hoc analysis from pirfenidone trials. • Overall no difference in morality data …
topic Yersinia pestis
gangrene
tobacco 21
continuous sympathetic blockade
triad asthma
coronary artery spasm
hypersensitivity pneumonitis
pirfenidone
idiopathic pulmonary fibrosis
mortality
url http://www.swjpcc.com/arizona-ats-notes/2018/3/28/march-2018-arizona-thoracic-society-notes.html
work_keys_str_mv AT robbinsra march2018arizonathoracicsocietynotes
_version_ 1725829687370842112